Recruiting
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
NCT07545122· Phase 1· Context Therapeutics Inc.· Source
Contact: Gavin Marx, Professor
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Contact: Relay Therapeutics, Inc
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· Phase 3· Celcuity Inc· Source
Contact: Nadene Zack, MS
Active, not recruiting
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT06970847· Phase 3· Clarity Pharmaceuticals Ltd· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· Phase 3· Hoffmann-La Roche· Source
Recruiting
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
NCT06714006· Phase 1· PYC Therapeutics· Source
Contact: Caitlin Cirera
Recruiting
Working Out M0 Bipolar Androgen Therapy
NCT06594926· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source
Contact: Gloria Jeong
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961· Phase 2/3· CSL Behring· Source
Contact: Trial Registration Coordinator
Active, not recruiting
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906· Phase 3· Bayer· Source
Active, not recruiting
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886· Phase 3· Celcuity Inc· Source
Recruiting
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
NCT05393791· Phase 2· Leiden University Medical Center· Source
Contact: Nina Singh
Active, not recruiting
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· Phase 3· HUYABIO International, LLC.· Source
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722· Phase 1/2· enGene, Inc.· Source
Contact: enGene clinical trials
Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source
Active, not recruiting
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System
NCT03626038· Zimmer Biomet· Source
Active, not recruiting
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients
NCT02922036· EBR Systems, Inc.· Source
Active, not recruiting
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
NCT02446444· Phase 3· University of Sydney· Source
Active, not recruiting
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446405· Phase 3· University of Sydney· Source
Active, not recruiting
Radiotherapy - Adjuvant Versus Early Salvage
NCT00860652· Trans Tasman Radiation Oncology Group· Source